Abstract

Objective To investigate the clinical significance of serum interferon (IFN) γ in patients with chronic hepatitis B (CHB).Methods Two hundred and eighty patients with CHB (CHBgroup) were divided into stabilize group (114 cases) and activity group (166 cases).Sixty healthy people were used as control group.The levels of serum IFN T and alanine aminotransferase (ALT) were measured with enzyme-linked immunosorbent assay.Results The levels of serum IFN γ and ALT in CHB group,stabilize group and activity group were significantly higher than those in control group [(114.54 ± 36.28),(54.21 ± 21.33) and (164.57 ± 41.25) ng/L vs.(26.43 ± 12.01) ng/L; (84.87 ± 45.24),(32.64 ± 15.59)and (93.26 ±41.55) U/L vs.(27.44 ± 11.52) U/L,P<0.05].The levels of serum IFN γ aad ALT in activity group were significantly higher than those in stabilize group (P< 0.05).The level of serum IFN γ in CHB patients was positively related with the level of serum ALT (r =0.504,P < 0.01).After treatment in activity group,there were 126 cases recovery,40 cases no-recovery,the levd of serum IFN γ in recovery patients was significantly lower than that in no-recovery patients [(76.24 ± 31.16) ng/L vs.(169.15 ± 39.46)ng/L,P <0.01].Conclusions The high-level expression of IFN T is found in CHB patients,and which maybe play a key role in the pathogenesis and progression of CHB patients.Regulation of immune responses maybe a new way in CHB. Key words: Hepatitis B,chronic; Hepatitis B virus; Interferon type Ⅱ

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.